President Xi recently pledged improvements to market access, IP protection, competitive markets, and monetary policy among other issues. Still, insufficient transparency surrounding opportunities for foreign companies to participate in projects continues to cloud companies’ strategic planning around BRI.
China Market Intelligence
The General Office of the State Council’s legislative work plan for 2018 indicates that several policies affecting foreign companies may be revised this year, including foreign investment restri
China’s moves, including environmental shutdowns, to cut production capacity have reduced supply, raised prices, and in some cases disrupted supply chains.
Recently announced provincial reimbursement drug lists (PRDLs) provide possible new opportunities for US pharmaceutical companies seeking to expand market reach for their drugs in China.
The 12th National People’s Congress (NPC) Standing Committee, which concluded its recent bimonthly session April 28 in Beijing, passed
Chief Financial Officers in China have a first-hand perspective on China’s slowing economic growth and its effect on company profit.
Companies can expect some openings in China’s newly issued list of industries off-limits to foreign investment in the recently unified free trade zones (FTZs), though many investment restrictions important to industry groups remain unchanged.
Last year, China’s 12th National People’s Congress (NPC) laid out a legislative agenda to address some of the most pressing issues facing the nation. And indeed, the topics discussed in 2014's NPC meeting did see movement.
The Chinese Communist Party released its fourth plenum decision document—a paper announcing the outcomes from its October “party-building” session—last night.
China’s Communist Party leadership today revealed incremental legal and corruption-related reforms at the close of its party governance meeting in Beijing.